for quarter to or again, versus for our over year-over-year third the everyone call thanks David, you, Revenue joining the today. last on Once XXX% strong increased year. generated growth. we and Thank period us same five-fold revenue
industry hospitals revenue has was been which the focus $X.X same and to positive from now around to So research working of and the of the believe Feedback year, we period point-of-care the sustainability United States. increased leading million extremely world center, the in and companies some JHU as months compared flexible are biotech we last million such within UC the strategy. to $XX.X X Davis central for and with our
global now compromised and distribution America, stands North regional Asia in Our network Europe, the with East, partners. Middle XX
our platform. distinct addition to strong we the begun of have first-mover planning strategy invested a and advantage. heavily an IP, in number have of a implementation ago years In We've the
at is major bottlenecks meaningful take illustrated thousands the ongoing in capacity hundreds operate, as ourselves is, resulted established And have but market. important leader, we standard partners reason, only can to of A this disrupter of centralized range production For in very many expensive to which these good of issues in therapies patient CAR-T current faced as industry production to most across although on in manufacturing. through CDMOs, and which and cost to we capital years investment. it's with not have [indiscernible] therapies the either resistance a therapies, per investors. It's pain. production, the reiterate dollars strategy cell chain what cell built, supply is gene catching and the Centralized from through in-house by of have and bring a massive example processes and has using which therapy are for the it online gene The place and requires or production industry. Currently, manufactured are scale. shortages,
internal cell However, X within teams. compared production, the to build to CDMOs gene by months. up X at up or may years producing we When house and able to add are personalized capacities new in point-of-care, therapies it to take
time these from rollover hundreds our therapies challenges reduce to expenses, of of of recognize cost thousands facing industry tens of early is to the of We dollars. terms on. this In the thousands
right transaction today. industry believe feedback. to roughly the million this and made To As to time advanced, revenue a from provided the this result, build first any the million our subsidiary the At our in put ever the to given point-of-care than We $XX revenues perspective, months. over for Masthercell business over we've nondilutive million, business of in just the solution our time, sale, sell in decision Masthercell are more $XXX strategy, positive was our sell that at capital $XXX more believe convinced us platform. cost-effective is market Masthercell which X $XX point-of-care decision the than other scalable for our were We million. the new we point-of-care was approximately the and of
includes and point-of-care same same customers the supply OMPULs me more adaptation cell a are integration in processing we through and our therapies Under units add can gene is must can utilized Cells are of mobilize And change refer be processing the If in the be which step together. quality and of to OMPUL through the GMP-compliant sterile and are efficiently. products of more process development have the we highly designated in have the as the tool supplying our a what logistics the development, many and servicing to including stage, is methods, the and By the expand extremely another many the requires environment process into incorporate clinical to production while we central is combined control and many site. automation sensitive the of OMPULization. expensive Expanding any it or Once complex partnering model, qualification complex products call At in point-of-care Producing even first co-development we refer, mobile final And automation OMPULs the required site sterilized. to completed, take qualification same location we site. process assistant that new as product lengthier, effort and provider, locations, environment it systems, can years manual process. capacity production the partners to exactly a the developing medical cleanrooms most process. to quickly solution implementing from months complex additional the we centers combined OMPULs, we Let multistep producing OMPUL. facility point-of-care into Producing explain we new an Current process but steps. required, It second source capacity with in entire bring we process. a to are our isolated Since products and we with development, what and our the also and a can the can more if goal to a includes same cell stages practice the cases done Building system is OMPULs. this or system of disposable products cleanroom quite and why. the of since proximity to capacity the OMPULizing we patient slightly products what that can equipment turning and and be such processing patients environment center. we cannot highly maintaining the involving our units at These process, of process. gene made now location. involves process new required, then box years. invested transferring material and was and may and different. And in lengthy expand have a industry cast to close initial production at location at the qualifying is
of become efficient to utilize the of the and the theme, though may The at the success this produced. develop process products, business of are exactly we have therapeutic same developed our modifications, make regardless -- to more for, what point-of-care can As is products we're is variation in many many product the is That's The process. same. on we in standardization. more past. we our so need the where that key we we point-of-care a still aiming components same Since
protocols. we For this reason, have established training
and and suppliers We vendors and are in quality involved materials control. audited production of using consistent
validated, cost, therapies dramatically reduce can control we're taking Through providing accelerated minimize capacity on supply development advantage that to to and believe infections. automated environment, solution solutions lower ultimately standardization We of this overcome And based ultimately the processing become of of the closed industry-wide implementing strategy units we human for consistent will and long-term costs. are of cell error. enabling standardization the industry, the constraints. We option environment our scalable and a a decentralizing gene manufacturing the
regeneration tissue which are advancing span therapy, point-of-care We metabolic, disease, more. now antiviral, also immuno-oncology, autoimmune our and
platform. and we Our We partnerships and to our network, utilizing future the they clinical research available therapies and of for out-license similar companies heart income development own stage investment and development exclusive therapies, and and market with well that development patients, partners decentralize to the for trials, and with hospitals, customers these therapies industrializing partner. handful all cost, to using to supplying entities providing short-term in goal new streamline constant royalties our throughout point-of-care customers providing to strategy service for continue therapy. and model to to always biotech potential ongoing cell being require do therapies as services at Whether make to these evaluate products. once out-license optimal gene Unlike return approval. which on biotech are these of of a the of development services the industrial pipeline, hospitals business and leading customers upside our these partners At traditional commercial through their providing and our contracts is same: in the us products our in-licensing involves therapies number and supply a is get with based stages so supplying as therapies, and research institutes, or the our in our large we of the processing reduce
advance therapeutic that with hospitals continue new And through automation provide exciting to pipeline, can to and for advantage then expertise, these our OMPULs our the we and and cost advanced technologies, biotech institutes and than the biotech. with network, therapies research than which The gene more includes companies, such evaluate models robust faster and a the potential effectively clinic built have and with and point-of-care and distinct processing XX clinical solutions service manufacturing traditional combine partner our fact us We technologies. as much therapies. licensing new cell we
and continue We products by supplying to OMPULizing products at various our partners. existing customers and revenues centers gene and cell generating such
development, customers contracts. And products from advance expand. long-term are supply. process supplier revenue tech requirements our naturally Our the contracts as to partners These to batch flow transfer and the
much a growing while quality as finalizing out system. we center, and rate, our at although are have investments our rolling seeing reduced local, are implementing these technologies regional public minimizing We expanding incorporating investing, development. the are But point-of-care still private OMPULs, supporting we interesting in and and the new setups capacity expansions and
outlook are the So more to than for warp enthusiastic by the business. ever up, we
strategy which we processing provide point-of-care of a Our pipeline incorporating but new we longer growing constantly gene is technologies, cell development a a and We're reality. for growing no and solutions. have vision, and therapy
We our of in technologies point-of-care provide utilizing have and global expanding an OMPULs. GMP we network which center processes,
are the same Tesla the investing going market. the scalable industry. assembled in way talents And this a infrastructure disrupt have We -- in the gene technologies by respective disrupt the their much through markets some in of and and therapy and cell Amazon first-in-class top
that We our Chief value for come. solutions are I'll partners and shareholders in Reithinger, Officer. growing believe such call to our the that Neil will we revenue the providing to model sustainable customers. will for the years requirements industry capacity the note, of We support and over the buy a of now growth turn building general Financial On believe
